Epidemiology & Outcomes Research
By impacting how we assess the end results of health care services, particularly prescription medications, outcomes research has significantly altered the culture of clinical practice and how choices are made in health care. What’s more, it has influenced how quality of care is measured.
“We are committed to enhancing quality of care through our innovative medicines," says David Boyko, M.D., senior vice president, Global Medical Affairs. "Providing information that fully describes the value of our products helps patients and their physicians make the right choices.”
At Bristol-Myers Squibb, Global Epidemiology and Outcomes Research works with compounds from early development through to market introduction. We use innovative techniques like mixed treatment meta-analyses, Markov chains, decision analytic models and non-experimental designs.
Our organization focuses on the value proposition of our products, or said another way, the reason(s) a patient, physician or payer would choose our product over other options. Our goal is to ensure that decision makers have the necessary information regarding benefits, risks, costs and the impact of our products to make informed decisions about each medicine’s appropriate place in patient treatment.
We welcome high achievers who are interested in — and comfortable with — the challenges of observational research. Appropriate backgrounds include epidemiology, medicine, health services research, economics, pharmacy and statistics.